Especially, the monoclonal antibodies targeting programmed death‐1 (PD‐1) and programmed death‐ligand 1 (PD‐L1) are under the spotlight as the standard of care to display momentous clinical benefits in many cancers.1 However, the current response rates on solid tumors are limited (10–35%),[1, 2, 3] and drug resistance is aggressively evolved in PD‐1/PD‐L1 blockades. The gene discussed is CD274; the disease is cancer.